Stewart D J, Goel R, Cripps M C, Huan S, Yau J, Verma S
Ontario Cancer Treatment and Research Foundation, University of Ottawa, Faculty of Medicine, Canada.
Invest New Drugs. 1997;15(4):267-77. doi: 10.1023/a:1005993705237.
Chemotherapy resistance is probably multifactorial; hence, we assessed the feasibility of adding to carboplatin 6 concurrent resistance modulators in 53 patients with resistant cancers.
Pentoxifylline and dipyridamole were added to carboplatin 400 mg/m2 in cohort 1, and metronidazole was also given in cohort 2. Mannitol and saline were administered in each cohort with the theoretical objective of improving carboplatin delivery to tumors by reducing blood viscosity. Because of excessive toxicity in cohort 2, cohort 3 received the same modulators as in cohort 2 but with a reduced dose of carboplatin (200 mg/m2). Subsequent patients had the following drugs added to those in the previous cohort: novobiocin (cohort 4), tamoxifen (cohort 5), ketoconazole (cohort 6). Cohort 7 patients received the 6 cohort 6 modulators along with carboplatin 300 mg/m2.
Thrombocytopenia was excessive in early cohorts with a carboplatin dose of 400 mg/m2, but was minimal at lower doses. Other toxicity was generally tolerable and reversible, particularly at carboplatin doses < or = 300 mg/m2, although gastrointestinal and neurological toxicity tended to worsen as additional modulators were added. No major responses (but 4 minor responses) were seen in this patient population with heavily pretreated or primarily resistant cancers.
Acceptable doses for phase II studies are carboplatin 300 mg/m2, 20% mannitol 250 ml plus normal saline 500 ml over 1 hr prior to carboplatin, pentoxifylline 700 mg/m2/day p.o. from 3 days before carboplatin to cessation of therapy, dipyridamole 100 mg/m2 p.o. q6h x 6 days starting 24 hr before carboplatin, metronidazole (750 mg/m2 p.o. 12 hr and immediately before, and 24 hr after carboplatin; 250 mg/m2 suppository p.r. 12 hr and immediately before, and 6 and 24 hr after carboplatin; and 500 mg/m2 i.v. right after carboplatin), novobiocin 600 mg/m2 p.o. q12h x 6 days starting 24 hr before carboplatin, and tamoxifen 100 mg/m2/day plus ketoconazole 700 mg/m2/day x 3 days starting the day before carboplatin, with oral dexamethasone and ondansetron as antimetics.
化疗耐药可能是多因素导致的;因此,我们评估了在53例耐药癌症患者中,于卡铂基础上加用6种同时使用的耐药调节剂的可行性。
在第1组中,己酮可可碱和双嘧达莫被添加到400mg/m²的卡铂中,第2组还给予甲硝唑。每组均给予甘露醇和生理盐水,理论目标是通过降低血液黏稠度来改善卡铂向肿瘤的输送。由于第2组毒性过大,第3组接受与第2组相同的调节剂,但卡铂剂量降低(200mg/m²)。随后的患者在前一组的基础上添加以下药物:新生霉素(第4组)、他莫昔芬(第5组)、酮康唑(第6组)。第7组患者接受第6组的6种调节剂以及300mg/m²的卡铂。
卡铂剂量为400mg/m²的早期组血小板减少过多,但在较低剂量时最少。其他毒性一般可耐受且可逆,尤其是卡铂剂量≤300mg/m²时,尽管随着添加更多调节剂,胃肠道和神经毒性有加重趋势。在这群接受过大量预处理或原发性耐药癌症的患者中,未观察到主要反应(但有4例轻微反应)。
II期研究的可接受剂量为卡铂300mg/m²,在卡铂前1小时静脉滴注20%甘露醇250ml加生理盐水500ml,从卡铂前3天至治疗结束口服己酮可可碱700mg/m²/天,从卡铂前24小时开始每6小时口服双嘧达莫100mg/m²共6天;甲硝唑(卡铂前12小时、即刻及卡铂后24小时口服750mg/m²;卡铂前12小时、即刻及卡铂后6小时和24小时直肠给药250mg/m²;卡铂后即刻静脉注射500mg/m²),从卡铂前24小时开始每12小时口服新生霉素600mg/m²共6天,从卡铂前一天开始他莫昔芬100mg/m²/天加酮康唑700mg/m²/天共3天,同时口服地塞米松和昂丹司琼作为止吐药。